KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accumulated Expenses (2020 - 2023)

AbCellera Biologics filings provide 4 years of Accumulated Expenses readings, the most recent being $3.1 million for Q3 2023.

  • Quarterly Accumulated Expenses fell 82.64% to $3.1 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Sep 2023, down 82.64% year-over-year, with the annual reading at $19.3 million for FY2022, 14.04% down from the prior year.
  • Accumulated Expenses hit $3.1 million in Q3 2023 for AbCellera Biologics, roughly flat from $3.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $27.1 million in Q4 2020 and bottomed at $595000.0 in Q3 2021.
  • Average Accumulated Expenses over 4 years is $14.0 million, with a median of $18.6 million recorded in 2022.
  • The largest annual shift saw Accumulated Expenses surged 2895.29% in 2022 before it crashed 82.64% in 2023.
  • AbCellera Biologics' Accumulated Expenses stood at $27.1 million in 2020, then dropped by 17.08% to $22.5 million in 2021, then dropped by 14.04% to $19.3 million in 2022, then crashed by 84.01% to $3.1 million in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Accumulated Expenses are $3.1 million (Q3 2023), $3.1 million (Q2 2023), and $3.1 million (Q1 2023).